Category Archives: Biotechnology

Mice Model Market: Expected Advancements & Global Industry Analysis 2023

Global Mice Model Market: Snapshot

Biomedical research has taken a front seat in the healthcare and pharmaceutical industries, to a point where a nation’s research and development landscape can be gauged by its level of investment in biomedical research. The past decade has consequently witnessed a staggering rise in biomedical research in most countries, both developed and developing. A significant part of this research investment typically goes into animal models, more specifically, mice models. This forms the primary driver for the global mice models market.

Another factor promoting the increased use of mice models is the recent number of improvements that have been made in mice models. These improvements have not only enhanced their utility in current applications, but also increased the overall scope of applications for mice models. Biomedical research can use mice models for increasingly complex diseases, such as the use of mutated mice models for studying the ALS disease, or the use of advanced mice models to understand lung injury repair.

This 155 page report gives readers a comprehensive overview of the mice model market. Browse through 20 data tables and 79 figures to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/mice-model-market.html

The factors above and similar ones that promote the use of mice models are responsible for imparting a positive growth rate to the global mice models market, which is expected to be valued at US$1.79 bn by the end of 2023.

Demand for Mice Models in North America Remains High

44.9% of the global market for mice models is expected to be held by North America in 2023, in terms of revenue. Europe at the same time is expected to emerge as the second-leading market for mice models, followed closely by Asia Pacific. North America and Europe have an established pharmaceutical industry and an advanced biosciences research field. Both regions are still showing a high demand for mice models that are meant to be used in advanced drug discovery processes and other medical research.

However, their overall share in the market value has dropped since 2014, owing to the significantly high demand for mice models in Asia Pacific. This region is showing an especially high demand for knockout and transgenic mice models. Close to half of the global mice models business in the world for these types is taken up by the Asia Pacific countries of China, India, Malaysia, and Singapore.

Inbred Mice Models Continue to Show High Demand, Demand for Hybrid Models on the Rise

Request a sample of this report to know what opportunities will emerge in the rapidly evolving mice model market during 2015 – 2023: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=2085

Based on model types, the global market for mice models is expected to progress at a CAGR of 6.4% from 2015 to 2023, ending at US$1.79 bn by the end of 2023. Among the various mice model types, inbred mice models have consistently been the popular ones, owing to the ease with which scientists can reproduce the data and the overall cost effective system of obtaining inbred mice models. Additionally, the size of samples in inbred mice models can be considerably smaller than their outbred counterparts.

However, the demand for congenic or hybrid mice models is expected to rise significantly over the coming years owing to a high preference for them in the expanding cardiovascular research. Transgenic mice models are the second most popular models in the world. They possess a high volume of research capability in the fields of angiogenesis, breast cancer, and Alzheimer’s disease.

The key providers of mice models from a global standpoint include Charles River Laboratories, The Jackson Laboratory, Harlan Laboratories, and Taconic Biosciences.

 

Bone Morphogenetic Proteins Market Overview – Key Futuristic Trends And Competitive Landscape 2022

A new Transparency Market Research report states that the global bone morphogenetic protein market was valued at US$612.601 mn in 2013.and is predicted to reach US$587.069 mn by 2022. It is expected to expand at a sluggish CAGR of 2.10% from 2014 to 2022. The title of the report is “Bone Morphogenetic Proteins Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2014 – 2022”.

This 65 page report gives readers a comprehensive overview of the bone morphogenetic proteins market. Browse through 13 data tables and 16 figures to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/bone-morphogenetic-protein-market.html

According to the report, the market for bone morphogenetic proteins is fuelled by the growing geriatric population, increasing sports and trauma injuries, and the increasing count of spinal fusion surgeries. In addition, the growing demand for minimally invasive surgeries and a rise in population having lower back pain issues will also augment the demand for bone morphogenetic proteins. On the other hand, factors such as the presence of a number of other bone graft substitutes and the detrimental side-effects caused by the off-label usage of bone morphogenetic proteins may impede the growth of the market in the coming years. Furthermore, the soaring costs of bone morphogenetic proteins may also pose a negative effect on the growth of the market.

The report segments the market on the basis of type into rhBMP-2 and rhBMP-7. Amongst these, in 2013, the segment of rhBMP-2 held the largest share in the market on the basis of revenue. This is because rhBMP-2 has been broadly accepted by surgeons and physicians globally owing to it being effective in carrying out lower back spinal fusions. On the other hand, the segment of rhBMP-7 is predicted to lose all of its market share in the forthcoming years owing to the elimination of OP-1/Opgenra from the market, starting from August 2014.

Request a sample of this report to know what opportunities will emerge in the rapidly evolving bone morphogenetic proteins market during 2014 – 2022: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=2308

On the basis of application, the report segments the market into trauma, spinal fusion, oral maxillofacial, and reconstructive surgery. Amongst these, the segment of spinal fusion holds the largest share in the market, trailed by the segment of trauma. On the other hand, the reconstructive segment is predicted to expand at low CAGR in the forecast horizon. This is owing to the availability of a number of promising bone graft alternatives and the limited utilization of bone morphogenetic protein products in reconstructive surgery.

On the basis of geography, the bone morphogenetic proteins market is segmented into Europe, North America, Asia Pacific, and Rest of the World (RoW). Amongst these, North America constitutes the largest share of more than 70% in the market for bone morphogenetic proteins and is predicted to lead the market all through the forecast horizon. This is due to the increasing awareness on bone morphogenetic protein products and the rising count of spinal fusion procedures.As per the report, the chief players operating in the market are Medtronic, Cellumed Co. Ltd., and Stryker Corporation, among others.

 

Transformative Effect of Regenerative Medicine on Human Health Benefits Global Market

Global Regenerative Medicine Market: Snapshot

Increasing application areas such as neurology, cardiovascular, musculoskeletal and orthopedic diseases will build up greater opportunities, states TMR. The market for regenerative medicine market appears to be fragmented in terms of competition. The Asia Pacific region will present large opportunities, displaying a promising CAGR between 2013 and 2019. The Asian countries such as South Korea, China, and Japan hold considerable prospects for augmentation of global regenerative medicine market. Smith & Nephew, a British medical equipment manufacturing company acquired Sushrut Surgical Pvt. Ltd., an India-based medical technology firm, enhancing access to the consumer pool in Asian countries in order to secure larger profits.

The global regenerative medicine market was pegged at US$2.5 mn in 2012. It is projected to achieve US$6.4 mn by the end of 2019, expanding at a progressive CAGR of 12.8% during the forecast period.

Read Full Report: http://www.transparencymarketresearch.com/regenerative-medicines-market.html

North America Leads Due to Increasing Bone and Joint Reconstructive Surgeries

North America, owing to a large number of leading companies operating in regenerative medicine, dominates the global regenerative medicine market. The ongoing expansive research and development activities in the U.S. will also drive the North America segment. The bone and joint regenerative medicine market is the leading application segment in this region, as a high demand for regenerative medicine is exhibited.

The region of Asia Pacific will witness monumental growth because of its massive consumer pool, rising disposable incomes of people, and growing healthcare expenditure. Over the coming years, the regenerative medicine market in Asia Pacific will benefit from the growing demand for orthopedic surgeries, technological innovations, high incidence of joint and bone diseases, and increasing awareness about regenerative medicine. However, the market might face challenges such as high costs and regulatory policies.

Japan displays great potential on account several favorable factors. Fewer regulatory restraints, coupled with technological advancements in the area of regenerative medicine will ensure market expansion in the country. One key technological development is the emergence of 3D tissue bioprinters that enable the creation of blood vessels, cartilage, skin and other tissues.

Download exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=419

Extensive Research in Stem Cell Therapy to Promote Growth

Bio-based alternatives such as stem cell therapy and tissue engineering have gained prominence despite the rapid development of synthetic options. The high generative power of stem cells enables the production of other cells in the body. This feature of stem cells has raised demand for stem cell therapies. Additionally, stem cell therapy is used in the treatment of diseases such as cancer, retinal diseases, Alzheimer’s, diabetes, heart failure treatment, rheumatoid arthritis, autism spectrum, multiple sclerosis, cerebral palsy, and osteoarthritis, among others. It is projected that stem cells will occupy an important portion of regenerative medicine market over the coming period. Therefore, large-scale research activities have been undertaken in order to tap their full potential. However, factors such as ethical issues related to the use of embryonic stem cells might pose a threat to further expansion.

Notwithstanding the advancement of the stem cell therapy segment, the biomaterials segment is expected to retain its foremost position in the global regenerative medicine market. The largest amount of shares were held by this segment in 2012 on account of great demand for biomaterials and supportive reimbursement policies.

The key players operating in the global regenerative medicine market are Stryker Corporation (Vitoss Bone Graft Substitute), DePuy Synthes, Inc. (Healos Bone Graft), CONMED Corporation, Arthrex, Inc., Zimmer Holdings, Inc. (CopiOs Bone Void Filler), and Medtronic, Inc.(INFUSE Bone Graft).

 

Global Life Science Reagents Industry: PCR Reagent Kits Market to Cannibalize Share of Other Product Markets

Life science refers to the scientific study of biology of living organisms such as human beings, microorganisms, animals and plants. Life science reagents support various life science techniques such as chromatography, flow cytometry and polymerase chain reaction (PCR) to speed up procedures, maintain the pH level of solutions or provide necessary chemical medium. Transparency Market Research (http://www.transparencymarketresearch.com/), a leading U.S.-based market research firm, analyzes the global market for life science reagents and predicts a compounded annual growth rate of 10.8% for the period 2013 to 2019.

Read Full Press Release: http://www.transparencymarketresearch.com/pressrelease/life-sciences-reagents-analytical-reagents.htm

The global life science reagents market has experienced tremendous growth in the last few decades. Life science reagents have been in use since 1940’s when cell culture and chromatography techniques were in developmental stage. Completion of human genome project fueled the use life science reagents in the healthcare industry especially in diagnosis and forensic applications. Furthermore, advancement in the field of chromatography, electrophoresis, flow cytometry and in-vitro diagnosis has led to expansion of the application area of these technologies in the healthcare and pharmaceutical industry. Opening out of application areas of biotechnology in pharmaceuticals and healthcare resulted in rapid growth of the life science reagents market.

With expansion in the number of global geriatric population, prevalence of diseases gradually increasing and thus has led to growth in demand for effective and accurate diagnostic tools. Growing in the demand for in-vitro diagnostic solutions is driving the life science reagents market towards growth.

The demand for advanced and improved diagnostic tools is also high in the area of drug research and development. In order to expand their market share in the life science industry, market players are investing heavily on biotechnology and drug research activities in order to introduce novel products in the market. Governments in emerging countries are offering partnerships and encouraging establishment of business clusters to set up biotechnology research facilities. In addition to partnerships, governments are also offering funding and tax benefits to boost the biotechnology industry in their countries. Growth in research activity in the field of biotechnology and drug development is stimulating the growth of life science reagents market.

Get a Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1162

Major players in the life science reagents market are increasingly entering the emerging markets of India, Brazil and China due to availability of qualified manpower, currency difference benefits and cheap labor. Furthermore, rapidly growing medical tourism industry in the Asia-Pacific regions will attract international patients, which will ultimately lead to growth in demand for advanced diagnostic tools and medical services. This market is characterized by the presence of several big and small-scale suppliers and thus has rendered it to be fragmented in nature. Some of the major companies contributing to the global life science reagents market are Abbott Laboratories, Agilent Technologies, Sigma Aldrich Corporation, Siemens Healthcare, Merck Millipore and Bio-Rad Laboratories, Inc.

Global Aptamer Market: Advancements in Aptamer Technology to Expand Market at 73.1% CAGR

Aptamers are chemically synthesized single stranded oligonucleotides that are used to inhibit variety of target proteins and antigens. Aptamers specifically bind to a range of micromolar to macromolar molecular targets. They are basically of two types namely nucleic acid aptamers and peptide aptamers. Nucleic acid aptamers have the strand of oligonucleotides while peptide aptamers contain short peptide domain in its structure. Normally aptamers can be generated by the aptamer selection process known as SELEX process. Aptamer technology applies in number of areas such as diagnostics, food safety, research applications and therapeutics in number of industrial sectors like pharmaceutical, research laboratories and biotechnology.

Read Full Report: http://www.transparencymarketresearch.com/aptamers-market.html

Transparency Market Research, a leading U.S based market research firm analyses the global market for aptamers and estimates the CAGR of 73.1% for the period 2013 – 2019. This is majorly due to increasing research and development activities by scientists coupled with increasing participation of government and private organizations in the U.S. and U.K. towards the development of this field. For example, in June 2014, Somalogic, Inc. received funding from Bill and Melinda Gates Foundation to develop SOMAmer based tuberculosis biomarker assay for the identification of patient’s tuberculosis.

The other factors such as advancement in aptamer selection technologies coupled with various advantages of aptamers over monoclonal antibodies will further drive the market growth. Several modifications of the SELEX procedure have been introduced to improve aptamer selectivity or to reduce selection time. Subtractive SELEX, automated SELEX and atomic force microscopy-SELEX are some of the modified SELEX processes available for aptamer selection with desired features. Companies like Archemix, Somalogic, Inc. and Aptamer Sciences, Inc. are constantly involved in collaboration strategy with number of biotechnology companies to develop their aptamer business. For example, Archemix collaborated with Elan to discover aptamers for treatment of autoimmune diseases. Thus, these types of collaboration will help companies to develop new aptamers hence drives the market growth. Moreover, large number companies have increased their research expenses on aptamers after first aptamer- Macugen approved by USFDA in 2004. For example, Germany-based NOXXAN Pharma AG has three aptamers namely NOX-E63, NOX A-12 and NOX-H94 under clinical pipeline. NOX-E63 and NOX A-12 are under phase II clinical studies. The approval of these aptamers in future would definitely boost the market growth of aptamers. Other features of aptamers like favorable toxicological property, high stability, ease of synthesis and rapid tissue penetration would significantly contribute to the growth of the market.

Download exclusive Sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1335

The factors mentioned above are driving the development and commercialization of aptamers worldwide. However, unfavorable regulatory environment, lack of universal rule coupled with lack of knowledge of aptamers among research scientists will restrain the market growth. For example, there is no formal regulatory guideline that can satisfactorily address the quality and safety of aptamer molecule. Additionally, countries like Europe demands tedious documentation to start clinical trials on aptamers which will further restrain the market growth of aptamers.